Zoledronic Acid in the Management of Patients With Asymptomatic/Early Stage Multiple Myeloma
Status:
Terminated
Trial end date:
2007-03-01
Target enrollment:
Participant gender:
Summary
Evidence for the beneficial effects of bisphosphonates on bone resorption in multiple myeloma
has been reported extensively, showing reductions in skeletal events and improvement of
several biochemical variables in bone resorption. Zoledronic acid (Zometa®, CGP42446) is the
most potent clinically available bisphosphonates, with the largest therapeutic ratio between
the desired inhibition of calcium resorption and the unwanted inhibition of mineralization in
vitro of all the bisphosphonates.
This trial will investigate the efficacy of zoledronic acid in preventing skeletal events in
patients with asymptomatic/early stage Multiple Myeloma